SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer.

Imaging in oncology is an essential tool for patient management but its potential is being profoundly underutilized. Each of the techniques used in the diagnostic process also conveys functional information that can be relevant in treatment decision-making. New imaging algorithms and techniques enhance our knowledge about the phenotype of the tumor and its potential response to different therapies. Functional imaging can be defined as the one that provides information beyond the purely morphological data, and include all the techniques that make it possible to measure specific physiological functions of the tumor, whereas molecular imaging would include techniques that allow us to measure metabolic changes. Functional and molecular techniques included in this document are based on multi-detector computed tomography (CT), 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), magnetic resonance imaging (MRI), and hybrid equipments, integrating PET with CT (PET/CT) or MRI (PET-MRI). Lung cancer is one of the most frequent and deadly tumors although survival is increasing thanks to advances in diagnostic methods and new treatments. This increased survival poises challenges in terms of proper follow-up and definitions of response and progression, as exemplified by immune therapy-related pseudoprogression. In this consensus document, the use of functional and molecular imaging techniques will be addressed to exploit their current potential and explore future applications in the diagnosis, evaluation of response and detection of recurrence of advanced NSCLC.

SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer. / Guía SEOM-SERAM-SEMNIM sobre el empleo de las técnicas de imagen funcional y molecular en el cáncer de pulmón no microcítico avanzado.

Imaging in oncology is an essential tool for patient management but its potential is being profoundly underutilized. Each of the techniques used in the diagnostic process also conveys functional information that can be relevant in treatment decision making. New imaging algorithms and techniques enhance our knowledge about the phenotype of the tumor and its potential response to different therapies. Functional imaging can be defined as the one that provides information beyond the purely morphological data, and include all the techniques that make it possible to measure specific physiological functions of the tumor, whereas molecular imaging would include techniques that allow us to measure metabolic changes. Functional and molecular techniques included in this document are based on multi-detector computed tomography (CT), 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), magnetic resonance imaging (MRI), and hybrid equipments, integrating PET with CT (PET/CT) or MRI (PET-MRI). Lung cancer is one of the most frequent and deadly tumors although survival is increasing thanks to advances in diagnostic methods and new treatments. This increased survival poises challenges in terms of proper follow-up and definitions of response and progression, as exemplified by immune therapy-related pseudoprogression. In this consensus document, the use of functional and molecular imaging techniques will be addressed to exploit their current potential and explore future applications in the diagnosis, evaluation of response and detection of recurrence of advanced NSCLC.

[Intrapericardial cisplatin for malignant tamponade]. / Cisplatino intrapericárdico en el taponamiento neoplásico.

The choice therapy of malignant pericardial effusion is controversial. Pericardiocentesis is usually successful in alleviating tamponade, but unfortunately, that tamponade recurs frequently and patients are then again exposed to a critical situation and need hospitalization. Several different approaches have been advocated in order to prevent reaccumulation of the pericardial fluid, most of them quite cumbersome. We present our experience with intrapericardial administration of cisplatin. There were 6 patients, and the primary tumor was breast carcinoma in 2, lung in 1, ovary in 1, mediastinal fibrosarcoma in 1, and unknown in 1. Administration of cisplatin was virtually uneventful and painless, and there were no recurrences, with a survival of 2 to 18 months (mean 5.6).We conclude that intrapericardial cisplatin is safe and effective in treating malignant pericardial tamponade and preventing recurrence.

SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer

Imaging in oncology is an essential tool for patient management but its potential is being profoundly underutilized. Each of the techniques used in the diagnostic process also conveys functional information that can be relevant in treatment decision-making. New imaging algorithms and techniques enhance our knowledge about the phenotype of the tumor and its potential response to different therapies. Functional imaging can be defined as the one that provides information beyond the purely morphological data, and include all the techniques that make it possible to measure specific physiological functions of the tumor, whereas molecular imaging would include techniques that allow us to measure metabolic changes. Functional and molecular techniques included in this document are based on multi-detector computed tomography (CT), 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), magnetic resonance imaging (MRI), and hybrid equipments, integrating PET with CT (PET/CT) or MRI (PET-MRI). Lung cancer is one of the most frequent and deadly tumors although survival is increasing thanks to advances in diagnostic methods and new treatments. This increased survival poises challenges in terms of proper follow-up and definitions of response and progression, as exemplified by immune therapy-related pseudoprogression. In this consensus document, the use of functional and molecular imaging techniques will be addressed to exploit their current potential and explore future applications in the diagnosis, evaluation of response and detection of recurrence of advanced NSCLC

No disponible

Pancreatic involvement detected with (18)F-FDG PET/CT in disseminated sarcoidosis.

La sarcoidosis is a granulomatous disease of unknown etiology. It may mimic malignancy and may affect multiple organs, with a variable clinical course. Pancreatic involvement is very rare. We present the case of a 78-year-old woman with systemic sarcoidosis whose (18)F-FDG PET/CT scan showed a pancreatic lesion and multiple lymphatic (thoracic and non-thoracic) and visceral lesions. The abnormal (18)F-FDG uptake in the pancreas was limited to the tail. A second (18)F-FDG PET/CT study performed 4 months and 3 weeks after the first PET/CT, following corticosteroid therapy during three and a half months, evidenced partial regression of the disease, with persistent (18)F-FDG pathological uptake in the pancreatic lesion.

Guía SEOM-SERAM-SEMNIM sobre el empleo de las técnicas de imagen funcional y molecular en el cáncer de pulmón no microcítico avanzado / SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer

En oncología, las técnicas de imagen son una herramienta esencial para el manejo de los pacientes, pero su potencial está enormemente infrautilizado. Cada una de las modalidades que se utilizan en el proceso diagnóstico ofrece, también, información funcional que puede ser relevante para el proceso de toma de decisiones en torno al tratamiento. Nuevos algoritmos y técnicas de imagen acentúan lo que ya sabemos del fenotipo del tumor y de su posible respuesta a diferentes tratamientos. Las modalidades de imagen funcional se definen como aquellas que ofrecen información más allá de los meros datos morfológicos e incluyen todas las técnicas que hacen posible medir funciones fisiológicas específicas del tumor, mientras que las modalidades de imagen molecular se refieren a técnicas que nos permiten medir cambios a nivel metabólico. Las técnicas funcionales y moleculares incluidas en el presente documento se basan en la tomografía computarizada (TC) multidetector, la tomografía por emisión de positrones con 18-fluorodesoxiglucosa (18F-FDG PET), la resonancia magnética (RM) y los equipos híbridos que integran la PET y la TC (PET/TC) o la PET y la RM (PET/RM). El cáncer de pulmón es uno de los tumores más comunes y letales que existen, aunque la supervivencia va en aumento gracias a los avances realizados en los métodos diagnósticos y a los nuevos tratamientos. Esta mayor supervivencia plantea retos en torno a un adecuado seguimiento y a las definiciones de respuesta y progresión de la enfermedad, tal y como ejemplifica la seudoprogresión de la enfermedad asociada a las terapias inmunológicas. En este documento de consenso abordamos el uso de las técnicas de imagen funcional y molecular a fin de poder explotar todo su potencial en la actualidad, y explorar futuras aplicaciones en el diagnóstico, evaluación de la respuesta al tratamiento y detección de la recurrencia del cáncer de pulmón no microcítico en fase avanzada

Imaging in oncology is an essential tool for patient management but its potential is being profoundly underutilized. Each of the techniques used in the diagnostic process also conveys functional information that can be relevant in treatment decision making. New imaging algorithms and techniques enhance our knowledge about the phenotype of the tumor and its potential response to different therapies. Functional imaging can be defined as the one that provides information beyond the purely morphological data, and include all the techniques that make it possible to measure specific physiological functions of the tumor, whereas molecular imaging would include techniques that allow us to measure metabolic changes. Functional and molecular techniques included in this document are based on multi-detector computed tomography (CT), 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), magnetic resonance imaging (MRI), and hybrid equipments, integrating PET with CT (PET/CT) or MRI (PET-MRI). Lung cancer is one of the most frequent and deadly tumors although survival is increasing thanks to advances in diagnostic methods and new treatments. This increased survival poises challenges in terms of proper follow-up and definitions of response and progression, as exemplified by immune therapy-related pseudoprogression. In this consensus document, the use of functional and molecular imaging techniques will be addressed to exploit their current potential and explore future applications in the diagnosis, evaluation of response and detection of recurrence of advanced NSCLC

Pancreatic involvement detected with 18F-FDG PET/CT in disseminated sarcoidosis

La sarcoidosis es una enfermedad granulomatosa de etiología desconocida. Puede simular malignidad y puede afectar a múltiples órganos, con una evolución clínica variable. La afectación del páncreas es excepcional. Se presenta el caso de una mujer de 78 años con sarcoidosis sistémica en la que la PET-TAC con 18F-FDG mostró una lesión pancreática y múltiples lesiones hipermetabólicas ganglionares (torácicas y extratorácicas) y viscerales. La captación patológica de 18F-FDG en páncreas se limitaba a la cola. Un segundo estudio PET-TAC con 18F-FDG realizado 4 meses y tres semanas después del primer estudio, tras haber aplicado terapia corticoidea durante 3,5 meses, evidenció una regresión parcial de la enfermedad, con una captación patológica persistente de 18F-FDG en la lesión pancreática(AU)

Sarcoidosis is a granulomatous disease of unknown etiology. It may mimic malignancy and may affect multiple organs, with a variable clinical course. Pancreatic involvement is very rare. We present the case of a 78-year-old woman with systemic sarcoidosis whose 18F-FDG PET/CT scan showed a pancreatic lesion and multiple lymphatic (thoracic and non-thoracic) and visceral lesions. The abnormal 18F-FDG uptake in the pancreas was limited to the tail. A second 18F-FDG PET/CT study performed 4 months and 3 weeks after the first PET/CT, following corticosteroid therapy during three and a half months, evidenced partial regression of the disease, with persistent 18F-FDG pathological uptake in the pancreatic lesion(AU)